Tonix Pharmaceuticals Holding (STU:TPM0) LT-Debt-to-Total-Asset : 0.05 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Tonix Pharmaceuticals Holding LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Tonix Pharmaceuticals Holding's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.05.

Tonix Pharmaceuticals Holding's long-term debt to total assets ratio increased from Mar. 2023 (0.00) to Mar. 2024 (0.05). It may suggest that Tonix Pharmaceuticals Holding is progressively becoming more dependent on debt to grow their business.

Tonix Pharmaceuticals Holding LT-Debt-to-Total-Asset Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding LT-Debt-to-Total-Asset Chart

Tonix Pharmaceuticals Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.05

Tonix Pharmaceuticals Holding Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	0.01	0.01	0.05	0.05

Tonix Pharmaceuticals Holding LT-Debt-to-Total-Asset Calculation

Tonix Pharmaceuticals Holding's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	6.596	/	141.637
	=	0.05

Tonix Pharmaceuticals Holding's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	6.183	/	124.516
	=	0.05

Tonix Pharmaceuticals Holding (STU:TPM0) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Tonix Pharmaceuticals Holding LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding (STU:TPM0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (STU:TPM0) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

TNXP:USA

Address

26 Main Street, Suite 101, Chatham, NJ, USA, 07928

Website

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Tonix Pharmaceuticals Holding (STU:TPM0) Headlines

No Headlines